Incyte registers Phase 2 FIGHT-214 trial of pemigatinib in cholangiocarcinoma

Incyte Corporation's registry activity included one new trial registration and an updated listing for a study it funds as a collaborator.

• A Phase 2, single-arm study called "FIGHT-214" will test pemigatinib in participants with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 fusion or rearrangements after at least 1 prior line of systemic therapy.¹ The study was first posted on 2026-10-07 and is listed as not yet recruiting, with an estimated start date of 2026-12-15¹, and plans to enroll 72 participants (estimated)¹, with the primary outcome being objective response, defined as having a confirmed best response of complete response or partial response, as determined by an independent central review per RECIST v1.1.¹
• A separate study called "TRIUMPH," sponsored by Oregon Health and Science University with Incyte Corporation as a collaborator, is testing topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers.² The record shows a start date of 2026-09-01 and a status of recruiting, with the posting itself last updated on 2026-10-09; the study plans to enroll approximately 12 adults (ages 18-99) with a PARACELSUS score >10 and a target ulcer ≤10 cm²,² with the primary endpoint being the proportion of participants achieving complete re-epithelialization of the target ulcer at Week 24.²